| Class | Adenosine receptor antagonist |
|---|---|
| Chemistry |
Methylxanthine |
| Routes of administration |
IV or oral |
| Absorption |
Well absorbed after oral administration, about 90% bioavailability |
| Solubility |
pKa = 5.0, good water solubility (much better than theophylline, which is why this is the IV alternative to it) |
| Distribution |
VOD=0.3-0.7L/kg, 60% protein-bound |
| Metabolism |
A pro-drug - really just an ethylenediamine salt of theophylline, and so it immediately dissociates into theophylline, which is the main pharmacologically active agent. |
| Elimination |
Minimal free drug is eliminated in the urine |
| Time course of action |
Half-lie of aminophylline itself is minuscule, whereas the half-life of theophylline is 8 hours. |
| Target receptor |
Adenosine A1 and A2 receptors, which inhibit neurotransmitter releease by regulating presynaptic potassium and calcium traffic. Also phospodiesterase type III and IV |
| Mechanism of action |
Multiple effects: |
| Clinical effects |
Bronchodilation, pulmonary arterial vasodilation, increased diaphragmatic contractility, tachycardia, increased cardiac output, arrhythmias, diuresis, increased gastric acid secretion, and rhabdomyolysis and seizures in overdose |
| Literature reference |
Stirt & Sullivan, 1981 |
| CICM details of understanding | Level 2 |
| Mentioned around Deranged Physiology |
Pharmacology of drugs used to treat asthma Also see Theophylline toxicity because they are basically the same drug |
| Related SAQs |
Question 11 from the second paper of 2023 |